Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Liabilities and Shareholders Equity (2016 - 2023)

Historic Liabilities and Shareholders Equity for Aptevo Therapeutics (APVO) over the last 9 years, with Q3 2023 value amounting to $27.1 million.

  • Aptevo Therapeutics' Liabilities and Shareholders Equity fell 1440.61% to $27.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was $125.2 million, marking a year-over-year decrease of 2731.27%. This contributed to the annual value of $34.2 million for FY2022, which is 3955.05% down from last year.
  • According to the latest figures from Q3 2023, Aptevo Therapeutics' Liabilities and Shareholders Equity is $27.1 million, which was down 1440.61% from $28.9 million recorded in Q2 2023.
  • Aptevo Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $80.8 million during Q1 2019, with a 5-year trough of $18.5 million in Q2 2020.
  • Over the past 5 years, Aptevo Therapeutics' median Liabilities and Shareholders Equity value was $45.2 million (recorded in 2022), while the average stood at $47.2 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first tumbled by 7200.99% in 2020, then surged by 28615.81% in 2021.
  • Quarter analysis of 5 years shows Aptevo Therapeutics' Liabilities and Shareholders Equity stood at $53.4 million in 2019, then grew by 0.26% to $53.5 million in 2020, then rose by 5.7% to $56.6 million in 2021, then plummeted by 39.55% to $34.2 million in 2022, then dropped by 20.71% to $27.1 million in 2023.
  • Its Liabilities and Shareholders Equity stands at $27.1 million for Q3 2023, versus $28.9 million for Q2 2023 and $35.0 million for Q1 2023.